Characterization of clinical phenotypes in congenital myasthenic syndrome associated with the c.1327delg frameshift mutation in chrne encoding the acetylcholine receptor epsilon subunit
Abstract: Background:Congenital myasthenic syndromes (CMS) are a group of rare but often treatable inherited disorders of neuromuscular transmission characterized by fatigable skeletal muscle weakness. In this paper we present the largest phenotypic analysis to date of a cohort of patients carrying the pathogenic variant c.1327delG in the CHRNE gene, leading to CHRNE-CMS.
Objective:This study aims to identify the phenotypic variability in CMS associated with c.1327delG mutation in the CHRNE gene.
Methods:Disease specific symptoms were assessed using specific standardized tests for autoimmune myasthenia (Quantitative Myasthenia Gravis score) as well as patient-reported scales for symptom severity. Evaluated clinical manifestations included ocular symptoms (ophthalmoparesis and ptosis), bulbar weakness, axial muscle weakness, proximal and distal muscle weakness, and respiratory function. Patients were allocated into three groups according to clinical impression of disease severity: mild, moderate, and severe.
Results:We studied 91 Bulgarian Roma patients, carrying the same causative homozygous CHRNE c.1327delG mutation. Bulbar weakness was present in patients throughout all levels of severity of CHRNE-CMS in this study. However, difficulties in eating and swallowing are more prominent characteristics in the moderate and severe clinical phenotypes. Diplopia and ptosis resulting from fatigue of the extraocular muscles were permanent features regardless of disease severity or age. Levels of axial, proximal and distal muscle weakness were variable between disease groups. The statistical analysis showed significant differences between the patients in the three groups, emphasizing a possible variation in symptom manifestation in the evaluated patient population despite the disease originating from the same genetic mutation. Impairment of respiratory function was more prominent in severely affected patients, which might result from loss of compensatory muscle function in those individuals.
Conclusion:Results from our study indicate significant phenotypic heterogeneity leading to mild, moderate, or severe clinical manifestation in CHRNE-CMS, despite the genotypic homogeneity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Journal of neuromuscular diseases. - 11, 5 (2024) , 1011-1020, ISSN: 2214-3602
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2025
- Urheber
-
Kastreva, Kristina
Chamova, Teodora
Blagoeva, Stanislava
Bichev, Stoyan
Mihaylova, Violeta
Meyer, Stefanie
Thompson, Rachel
Cherninkova, Sylvia
Guergueltcheva, Velina
Lochmüller, Hanns
Tournev, Ivailo
- DOI
-
10.3233/jnd-230235
- URN
-
urn:nbn:de:bsz:25-freidok-2617083
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kastreva, Kristina
- Chamova, Teodora
- Blagoeva, Stanislava
- Bichev, Stoyan
- Mihaylova, Violeta
- Meyer, Stefanie
- Thompson, Rachel
- Cherninkova, Sylvia
- Guergueltcheva, Velina
- Lochmüller, Hanns
- Tournev, Ivailo
- Universität
Entstanden
- 2025
Ähnliche Objekte (12)
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A deficiency in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) in skeletal muscle eesults in eeduced glycosylation of the delta subunit of the nicotinic acetylcholine receptor (AChRδ)
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Clinical outcomes in Duchenne Muscular Dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A deficiency in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) in skeletal muscle eesults in eeduced glycosylation of the delta subunit of the nicotinic acetylcholine receptor (AChRδ)
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Clinical outcomes in Duchenne Muscular Dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
A deficiency in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) in skeletal muscle eesults in eeduced glycosylation of the delta subunit of the nicotinic acetylcholine receptor (AChRδ)
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations